Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2025 · 10-Q
Revenue$491.00K$491.00K+11.3% vs Q3 2024 Net Income-$580.00K-$580.00KN/M vs Q3 2024 EPS Diluted-$0.01-$0.01N/M vs Q3 2024 Gross Profit$283,000+9.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$512,000N/M Margins · derivedGross margin57.6%−0.9 pt vs Q3 2024
Operating margin-118.9%+66.3 pt vs Q3 2024
Net margin-118.1%+76.2 pt vs Q3 2024
ended Apr 30, 2025 · filed Jun 16, 2025 · 47 d after period end